Science
iOS
AndroidMore Episodes
Collaboration in chronic ITP: Improving quality of life and patient outcomes - touchSYMPOSIUM for touchONCOLOGY
2025-01-21
Collaboration in chronic ITP: Improving quality of life and patient outcomes - touchSYMPOSIUM for touchHAEMATOLOGY
2025-01-21
Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchONCOLOGY
2025-01-06
Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchNEUROLOGY
2025-01-06
Advancing the treatment of muscle-invasive bladder cancer: Updates on immunotherapy in the perioperative setting
2024-12-19
Navigating treatment choices in high-risk early-stage melanoma - touchDERMATOLOGY
2024-12-17
Navigating treatment choices in high-risk early-stage melanoma - touchONCOLOGY
2024-12-17
Advances in IOL technology and power calculations: Updates and innovations from 2024
2024-12-04
Supporting healing in epidermolysis bullosa: Innovations and new directions for care
2024-11-27
Primary biliary cholangitis: Appraising the changing therapeutic landscape
2024-11-14
Primary biliary cholangitis: Appraising the changing therapeutic landscape
2024-11-14
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4
2024-11-14
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3
2024-11-14
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4
2024-11-14
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3
2024-11-14
touchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?
2024-11-13
touchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?
2024-11-13
touchMDT for touchRESPIRATORY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?
2024-11-13
touchMDT for touchONCOLOGY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?
2024-11-13
touchMDT for touchONCOLOGY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?
2024-11-13
